Malignant Thoracic Neoplasm Clinical Trial
Official title:
SyMPLER: Patient- and Caregiver-Triggered Palliative Referrals Via an Electronic Symptom Monitoring Program
This clinical trial evaluates earlier symptom management through remote electronic symptom monitoring (such as through an app on patient's phone), and accessibility of palliative care self-referral by patients with thoracic cancer and caregivers by proxy (legal representative). Thoracic cancer occurs in the chest and often causes symptoms for patients. Patients and/or their caregivers are often unable to attend in-person clinic visits for various reasons. The most frequently reported symptom by patients at initial palliative care consultations is pain, and caregivers' most common concerns are pain management for the patient, stress reduction, and fears about patient decline. Earlier palliative care referral can help control these symptoms before they worsen, providing a better quality of life for patients and caregivers. improve physical and emotional functioning for patients and caregivers in cancer care. This study may help researchers learn how an electronic symptom monitoring program may provide an earlier and more accessible way for patients with thoracic cancer to receive palliative care.
Status | Recruiting |
Enrollment | 157 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - PATIENTS: Age = 18 years - PATIENTS: Diagnosed with any stage (1-4) or type (non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic carcinoma) of thoracic malignancy - PATIENTS: = 2 visits at the Ohio State University Comprehensive Cancer Center (OSUCCC) Thoracic Oncology Clinic - PATIENTS: Study enrollment within 12 weeks of initial Thoracic Medical Oncology appointment - PATIENTS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means) - PATIENTS: Ability to read and understand English - PATIENTS: Access to a device with email or text messaging capability - CAREGIVERS: Age = 18 years - CAREGIVERS: Identified by patient participant as primary caregiver - CAREGIVERS: Corresponding patient participant has consented to participate in the study - CAREGIVERS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means) - CAREGIVERS: Ability to read and understand English - CAREGIVERS: Access to a device with email or text messaging capability Exclusion Criteria: - PATIENTS: Patients who have been previously referred to ambulatory palliative care are excluded from participation - PATIENTS: Prisoners are excluded from participation - PATIENTS: Pregnant patients are excluded from participation - PATIENTS: Patients who lack capacity for medical decision-making as determined by their primary oncologist are excluded from participation - PATIENTS: There is NO exclusion criteria pertaining to Eastern Cooperative Oncology Group (ECOG) performance status, laboratory values, prior cancer diagnoses, presence of comorbidities or brain metastases |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University Comprehensive Cancer Center | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center | National Comprehensive Cancer Network |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of symptom logging | Will estimate that = 50% of patient participants will log symptoms at least monthly through the remote electronic symptom monitoring program. | At 6 months after enrollment | |
Primary | Proportion of patients enrolled (Feasibility) | Descriptive statistics will include study enrollment rates (eligible vs. ineligible participants, consented vs. refused), completion rate of weekly symptom monitoring (patient vs. caregiver by proxy), and person requesting palliative care services (patient vs. caregiver by proxy vs. medical provider), if applicable. Will be considered feasible if within 20% of target enrollment. | At enrollment and 3 months | |
Primary | Symptom scores and Palliative Referral Association | Symptom scores (Edmonton Symptom Assessment Scale revised with Constipation and Sleep [ESAS-r-CS]) reported by patients and caregivers will be tracked and their association with palliative care referral, if applicable, will be assessed. | At enrollment and 3 months and 6 months | |
Primary | Patient and Caregiver Symptom Reporting Congruency | Descriptive statistics will be used to assess for congruency between patient and proxy-reported symptom assessments. Patients' oncologic treatment (chemotherapy, immunotherapy, radiation therapy, surgery) will be abstracted from the electronic medical record (EMR) at the time of each ESAS-r-CS survey completed by either the patient or caregiver by proxy. | At enrollment and 3 months and 6 months | |
Secondary | Palliative care referral patterns | Palliative care referrals pre- and post- launch of the SyMPLER study will be evaluated for trends. Historical control data collecting palliative referrals by month will be compared between groups (pre-post- launch). | Up to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
Recruiting |
NCT06456411 -
Functional Near-Infrared Spectroscopy and Virtual Reality Relaxation Programs for Pain Management in Patients With Cancer
|
||
Active, not recruiting |
NCT03868579 -
Rapid On Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy
|
N/A | |
Recruiting |
NCT04963972 -
Digital and Behavioral Tele-Health Tapering Program for Lowering Dependence on Opioids in Patients Undergoing Surgery
|
N/A | |
Completed |
NCT05793957 -
Use of Virtual Reality Goggles During Chemotherapy Infusion to Reduce Anxiety-Related Symptoms
|
N/A |